Qiagen NV (QGEN)
40.04
+0.58
(+1.46%)
USD |
NYSE |
Apr 19, 15:47
Qiagen Cash from Investing (TTM)
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2022 | -726.76M |
| September 30, 2022 | -506.95M |
| June 30, 2022 | -681.53M |
| March 31, 2022 | -614.65M |
| December 31, 2021 | -202.43M |
| September 30, 2021 | -352.22M |
| June 30, 2021 | -455.07M |
| March 31, 2021 | -350.42M |
| December 31, 2020 | -443.28M |
| September 30, 2020 | -469.49M |
| June 30, 2020 | -160.82M |
| March 31, 2020 | -38.56M |
| December 31, 2019 | -222.28M |
| September 30, 2019 | -120.36M |
| June 30, 2019 | -219.24M |
| March 31, 2019 | -490.48M |
| December 31, 2018 | -211.36M |
| September 30, 2018 | -324.96M |
| June 30, 2018 | -505.22M |
| March 31, 2018 | -344.14M |
| December 31, 2017 | -464.26M |
| September 30, 2017 | -387.68M |
| June 30, 2017 | -151.43M |
| March 31, 2017 | -208.33M |
| December 31, 2016 | -179.06M |
| Date | Value |
|---|---|
| September 30, 2016 | -292.31M |
| June 30, 2016 | -231.95M |
| March 31, 2016 | -155.35M |
| December 31, 2015 | -146.20M |
| September 30, 2015 | -143.96M |
| June 30, 2015 | -150.16M |
| March 31, 2015 | -292.90M |
| December 31, 2014 | -407.60M |
| September 30, 2014 | -295.44M |
| June 30, 2014 | -392.57M |
| March 31, 2014 | -316.39M |
| December 31, 2013 | -251.74M |
| September 30, 2013 | -315.25M |
| June 30, 2013 | -253.92M |
| March 31, 2013 | -299.09M |
| December 31, 2012 | -300.89M |
| September 30, 2012 | -259.41M |
| June 30, 2012 | -595.48M |
| March 31, 2012 | -477.24M |
| December 31, 2011 | -540.32M |
| September 30, 2011 | -569.18M |
| June 30, 2011 | -241.40M |
| March 31, 2011 | -225.61M |
| December 31, 2010 | -215.51M |
| September 30, 2010 | -331.95M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-726.76M
Minimum
Dec 2022
-38.56M
Maximum
Mar 2020
-370.94M
Average
-352.22M
Median
Sep 2021
Cash from Investing (TTM) Benchmarks
| MoonLake Immunotherapeutics | -25.18M |
| LENZ Therapeutics Inc | -- |
| Thermo Fisher Scientific Inc | -5.142B |
| uniQure NV | -205.69M |
| ProQR Therapeutics NV | 4.631M |